Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Authors	FAZIO Nicola MARTINI Jean-Francois CROITORU Adina E. SCHENKER Michael LI Sherry ROSBROOK Brad FERNANDEZ Kathrine TOMÁŠEK Jiří THIIS-EVENSEN Espen KULKE Matthew RAYMOND Eric
Year of publication	2019
Type	Article in Periodical
Magazine / Source	Future Oncology
MU Faculty or unit	Faculty of Medicine
Citation
web	http://dx.doi.org/10.2217/fon-2018-0934
Doi	http://dx.doi.org/10.2217/fon-2018-0934
Keywords	biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF
Description	Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.